HIGHLIGHTS
- who: Palittiya Sintusek and collaborators from the Thai Red Cross Society, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand have published the research: Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents, in the Journal: Vaccines 2022, 10, 1324. of 11/03/2020
- what: Since BNT162b2 was approved to prevent COVID-19 in children the authors aim to compare the safety and immunogenicity of the BNT162b2 vaccine in_(LT) and healthy LT and healthy received two doses of 30 µg of BNT162b2. This study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.